This Funding Opportunity Announcement (FOA) issued by the National
Institute of Allergy and Infectious Diseases (NIAID), National Institutes of
Health (NIH), invites research applications for projects focused on preclinical
development of candidate technologies (including adjuvants) that would improve
vaccine effectiveness and/or simplify vaccine delivery to patient populations
during a natural outbreak of an infectious disease or following the intentional
release of an infectious agent. Applications must include a Product Development
Strategy attachment and demonstrate substantive investment by at least one
industrial participant.
Letter of intent due date: May 26, 2012
Award budget: Budgets for direct costs of up to $750,000 per year
may be requested. In addition, applicants may request up to a total of $300,000 for major equipment in
the first year of the award to ensure that research aims can be met and
biohazards can be contained.
Scope of the proposed project should determine the project
period. The maximum period
is 5 years.
For further information, see: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12-014.html
